Evidence map›Paper›PMID 26191056›Full record

ArticleFrontiers in microbiology2015

CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.

Jianming Tang, Xuelin Li, Matthew A Price, Eduard J Sanders, Omu Anzala, Etienne Karita, Anatoli Kamali, Shabir Lakhi, Susan Allen, Eric Hunter and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Human Immunodeficiency Virus Infection and Host Defense in the Lungs.Seminars in respiratory and critical care medicine · 2016
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Jianming TangDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL USA.
Xuelin LiDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL USA.
Matthew A PriceInternational AIDS Vaccine Initiative, New York, NY USA ; Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA USA.
Eduard J SandersCentre for Geographic Medicine Research, Kenya Medical Research Institute, Kilifi Kenya ; Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford UK.
Omu AnzalaKenya AIDS Vaccine Initiative, Nairobi Kenya.
Etienne KaritaProjet San Francisco, Kigali Rwanda.
Anatoli KamaliUganda Virus Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Masaka Uganda.
Shabir LakhiZambia-Emory HIV Research Project, Lusaka Zambia.
Susan AllenZambia-Emory HIV Research Project, Lusaka Zambia ; Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA USA.
Eric HunterEmory Vaccine Center, Emory University, Atlanta, GA USA.
Richard A KaslowDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL USA.
Jill GilmourInternational AIDS Vaccine Initiative, Human Immunology Laboratory, Chelsea and Westminster Hospital, London UK.
University of Alabama at Birmingham · USEmory University · USChelsea and Westminster Hospital · GBInternational AIDS Vaccine Initiative · USKenya AIDS Vaccine Initiative · KEUganda Virus Research Institute · UGUniversity of Oxford · GB

Funding

CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
EMORY AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW001042 · FIC · EMORY UNIVERSITY · PI DEL RIO, CARLOS · 1998 to 2013
$6.8M
Host Genetic Epidemiology in HIV-1-Discordant African Couples and Other CohortsR01AI071906 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TANG, JIANMING · 2008 to 2012
$3.8M
FIC NIH HHS D43 TW001042NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI071906Wellcome Trust 092654
6 · The paper itself

Abstract

In individuals with human immunodeficiency virus type 1 (HIV-1) infection, CD4:CD8 lymphocyte ratio is often recognized as a quantitative outcome that reflects the critical role of both CD4(+) and CD8(+) T-cells in HIV-1 pathogenesis or disease progression. Our work aimed to first establish the dynamics and clinical relevance of CD4:CD8 ratio in a cohort of native Africans and then to examine its association with viral and host factors, including: (i) length of infection, (ii) demographics, (iii) HIV-1 viral load (VL), (iv) change in CD4(+) T-lymphocyte count (CD4 slope), (v) HIV-1 subtype, and (vi) host genetics, especially human leukocyte antigen (HLA) variants. Data from 499 HIV-1 seroconverters with frequent (monthly to quarterly) follow-up revealed that CD4:CD8 ratio was stable in the first 3 years of infection, with a modest correlation with VL and CD4 slope. A relatively normal CD4:CD8 ratio (>1.0) in early infection was associated with a substantial delay in disease progression to severe immunodeficiency (<350 CD4 cells/μl), regardless of other correlates of HIV-1 pathogenesis (adjusted hazards ratio (HR) = 0.43, 95% confidence interval (CI) = 0.29-0.63, P < 0.0001). Low VL (<10,000 copies/ml) and HLA-A*74:01 were the main predictors of CD4:CD8 ratio >1.0, but HLA variants (e.g., HLA-B*57 and HLA-B*81) previously associated with VL and/or CD4 trajectories in eastern and southern Africans had no obvious impact on CD4:CD8 ratio. Collectively, these findings suggest that CD4:CD8 ratio is a robust measure of immunologic health with both clinical and epidemiological implications.

Indexed as

AfricaCD4:CD8 ratioHIV-1HLAstatistical modelssubtypeviral load

Identifiers

PMID26191056
PMCPMC4486831
OpenAlexW1544798159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.